Tag: licensing
-
Neuro Therapy Company Spins-Off, Gains $20.8M Funding
A company developing treatments for cognitive impairment and Alzheimer’s disease is starting-up in Belgium, with a technology and financial backing from local and global businesses and investors.
-
Biotech, Univ. Lab Partner on Stem Cells for Alzheimer’s
A biotechnology company specializing in stem cell therapeutics is licensing a process from Texas A&M University to produce exosomes — cellular delivery packages — from adult stem cells as possible therapies for Alzheimer’s disease.
-
Pharma Maker Crowdsourcing for Drug Delivery Partners
The global pharmaceutical company AstraZeneca is looking for collaborators to develop treatments for disease using nucleic acids delivered with cell-penetrating peptides.
-
Engineered T-Cells Show Extended Leukemia Remission
A clinical trial shows a patient’s immune system cells, modified to add cancer-fighting proteins, can extend high remission among children with a type of leukemia for as long as 12 months, but also with high rates of adverse effects.
-
T-Cell Therapy Company Gains $100M in Venture Funds
A 2 year-old company developing treatments for cancer and other diseases that activate or suppress the immune system with genetically engineered T-cells is raising $100 million in its first venture funding round.
-
Start-Up Licenses Children’s Myopia-Control Contact Lens
A start-up enterprise spun-off from Hong Kong Polytechnic University is licensing the technology for a customized contact lens that controls and prevents further myopia in children.
-
Institute, Company Partner on Implanted Neuro Device
A research center in Switzerland and medical engineering company in Germany are developing an implanted device to measure signals and treat disorders affecting the brain.
-
Celgene Acquires Cancer Drug Start-Up in $7B Deal
The biopharmaceutical company Celgene Corp. is acquiring Impact Biomedicines Inc., a developer of drugs to treat a type of blood-related cancer, in a deal valued as much as $7 billion.
-
Sangamo, Pfizer Partner on ALS Gene Therapy
Drug maker Pfizer Inc. is licensing and collaborating on a gene therapy technology from Sangamo Therapeutics Inc. to treat amyotrophic lateral sclerosis, or ALS, and a related neurodegenerative disease.
-
RNA Therapies Start-Up Raises $55.3M in Early Funds
A start-up company creating treatments for inherited diseases that target faulty RNA transcribed from genetic codes is raising $55.3 million in its first venture funding round.